Abstract
Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.
Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fraction
Conclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Journal of Heart Failure |
| Vol/bind | 22 |
| Udgave nummer | 11 |
| Sider (fra-til) | 2160-2171 |
| ISSN | 1388-9842 |
| DOI | |
| Status | Udgivet - 2020 |
Adgang til dokumentet
- 10.1002/ejhf.2015Licens: CC BY-NC
- OA-Omecamtiv mecarbil in chronic heart failure with reduced ejection fractionForlagets udgivne version, 854 KBLicens: CC BY-NC
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction : GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. / Teerlink, John R.; Diaz, Rafael; Felker, G. Michael; McMurray, John J. V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias-Mendoza, Alexandra; Biering-Sorensen, Tor; Bohm, Michael; Bonderman, Diana; Cleland, John G. F.; Corbalan, Ramon; Crespo-Leiro, Maria G.; Dahlstrom, Ulf; Echeverria Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Candida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin-ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J. A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E.; GALACTIC HF Investigators.
I: European Journal of Heart Failure, Bind 22, Nr. 11, 2020, s. 2160-2171.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction
T2 - GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
AU - Teerlink, John R.
AU - Diaz, Rafael
AU - Felker, G. Michael
AU - McMurray, John J. V.
AU - Metra, Marco
AU - Solomon, Scott D.
AU - Adams, Kirkwood F.
AU - Anand, Inder
AU - Arias-Mendoza, Alexandra
AU - Biering-Sorensen, Tor
AU - Bohm, Michael
AU - Bonderman, Diana
AU - Cleland, John G. F.
AU - Corbalan, Ramon
AU - Crespo-Leiro, Maria G.
AU - Dahlstrom, Ulf
AU - Echeverria Correa, Luis E.
AU - Fang, James C.
AU - Filippatos, Gerasimos
AU - Fonseca, Candida
AU - Goncalvesova, Eva
AU - Goudev, Assen R.
AU - Howlett, Jonathan G.
AU - Lanfear, David E.
AU - Lund, Mayanna
AU - Macdonald, Peter
AU - Mareev, Vyacheslav
AU - Momomura, Shin-ichi
AU - O'Meara, Eileen
AU - Parkhomenko, Alexander
AU - Ponikowski, Piotr
AU - Ramires, Felix J. A.
AU - Serpytis, Pranas
AU - Sliwa, Karen
AU - Spinar, Jindrich
AU - Suter, Thomas M.
AU - Tomcsanyi, Janos
AU - Vandekerckhove, Hans
AU - Vinereanu, Dragos
AU - Voors, Adriaan A.
AU - Yilmaz, Mehmet B.
AU - Zannad, Faiez
AU - Sharpsten, Lucie
AU - Legg, Jason C.
AU - Abbasi, Siddique A.
AU - Varin, Claire
AU - Malik, Fady I.
AU - Kurtz, Christopher E.
AU - GALACTIC HF Investigators
PY - 2020
Y1 - 2020
N2 - Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fractionConclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
AB - Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fractionConclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
KW - Heart failure
KW - Omecamtiv mecarbil
KW - Cardiac myosin activator
KW - Inotrope
KW - Myotrope
KW - Cardiovascular outcomes trial
KW - CARDIAC MYOSIN ACTIVATOR
KW - INCREASE CONTRACTILITY
KW - TOLVAPTAN
KW - MORTALITY
KW - OUTCOMES
KW - PHASE-2
KW - WOMEN
U2 - 10.1002/ejhf.2015
DO - 10.1002/ejhf.2015
M3 - Journal article
C2 - 32985088
VL - 22
SP - 2160
EP - 2171
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1567-4215
IS - 11
ER -